N,N dimethylglycine and epilepsy.
Nineteen institutionalized patients with frequent seizures (group average two to three per day; seizure types--generalized, akinetic/myoclonic), were treated randomly with either placebo or N,N dimethylglycine (DMG) for 28 days. Dosage was 300 mg/day for the first 14 days and then 600 mg/day. Plasma levels were measured at baseline, days 2, 5, 8, 15, 22, 30, and 1 and 2 weeks after the study ended. No differences in seizure frequency were noted between placebo and DMG or between baseline and test conditions. No toxicity was noted.
Gascon
G
G
Department of Neuroscience, University of North Dakota School of Medicine, Fargo.
Patterson
B
B
Yearwood
K
K
Slotnick
H
H
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000097:blood / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012521:Sarcosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000927:Anticonvulsants; C025138:dimethylglycine; D005998:Glycine; D012521:Sarcosine